Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Diabetologia ; 50(1): 84-93, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17131143

ABSTRACT

AIMS/HYPOTHESIS: Levels of uncoupling protein-2 (UCP2) are regulated in the pancreatic beta cells and an increase in the protein level has been associated with mitochondrial uncoupling and alteration in glucose-stimulated insulin secretion. However, it is not clear whether an increase in uncoupling protein-2 per se induces mitochondrial uncoupling and affects ATP generation and insulin secretion. MATERIALS AND METHODS: Transgenic mice with beta cell-specific overexpression of the human UCP2 gene and INS-1 cells with doxycycline-inducible overproduction of the protein were generated and the consequences of increased levels of UCP2 on glucose-induced insulin secretion and on parameters reflecting mitochondrial uncoupling were determined. RESULTS: In transgenic mice, an increase in beta cell UCP2 protein concentration did not significantly modify plasma glucose and insulin levels. Glucose-induced insulin secretion and elevation in the ATP/ADP ratio were unaltered by an increase in UCP2 level. In INS-1 cells, a similar increase in UCP2 level did not modify glucose-induced insulin secretion, cytosolic ATP and ATP/ADP ratio, or glucose oxidation. Increased levels of UCP2 did not modify the mitochondrial membrane potential and oxygen consumption. Increased UCP2 levels decreased cytokine-induced production of reactive oxygen species. CONCLUSION/INTERPRETATION: The results obtained in transgenic mice and in the beta cell line do not support the hypothesis that an increase in UCP2 protein per se uncouples the mitochondria and decreases glucose-induced insulin secretion. In contrast, the observation that increased UCP2 levels decrease cytokine-induced production of reactive oxygen species indicates a potential protective effect of the protein on beta cells, as observed in other cell types.


Subject(s)
Glucose/pharmacology , Insulin-Secreting Cells/metabolism , Insulin/metabolism , Ion Channels/metabolism , Mitochondrial Proteins/metabolism , Reactive Oxygen Species/metabolism , Adenosine Triphosphate/metabolism , Animals , Cell Line , Cell Respiration/physiology , Doxycycline/pharmacology , Female , Glucose/metabolism , Ion Channels/genetics , Male , Membrane Potential, Mitochondrial/physiology , Mice , Mice, Transgenic , Mitochondrial Proteins/genetics , Uncoupling Protein 2
2.
Diabetes ; 50(4): 803-9, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11289045

ABSTRACT

The mechanism by which long-term exposure of the beta-cell to elevated concentrations of fatty acid alters glucose-induced insulin secretion has been examined. Exposure of INS-1 beta-cells to 0.4 mmol/l oleate for 72 h increased basal insulin secretion and decreased insulin release in response to high glucose, but not in response to agents acting at the level of the K(ATP) channel (tolbutamide) or beyond (elevated KCl). This also suppressed the glucose-induced increase in the cellular ATP-to-ADP ratio. The depolarization of the plasma membrane promoted by glucose was decreased after oleate exposure, whereas the response to KCl was unchanged. Cells exposed to free fatty acids displayed a lower mitochondrial membrane potential and a decreased glucose-induced hyperpolarization. The possible implication of uncoupling protein (UCP)-2 in the altered secretory response was examined by measuring UCP2 gene expression after chronic exposure of the cells to fatty acids. UCP2 mRNA and protein were increased twofold by oleate. Palmitate and the nonoxidizable fatty acid bromopalmitate had similar effects on UCP2 mRNA, suggesting that UCP2 gene induction by fatty acids does not require their metabolism. The data are compatible with a role of UCP2 and partial mitochondrial uncoupling in the decreased secretory response to glucose observed after chronic exposure of the beta-cell to elevated fatty acids, and suggest that the expression and/or activity of the protein may modulate insulin secretion in response to glucose.


Subject(s)
Fatty Acids/metabolism , Glucose/physiology , Insulin/metabolism , Membrane Transport Proteins , Mitochondrial Proteins , Proteins/physiology , Adenosine Diphosphate/metabolism , Adenosine Triphosphate/metabolism , Blood Physiological Phenomena , Cell Line , Fatty Acids/pharmacology , Gene Expression/drug effects , Insulin Antagonists/pharmacology , Insulin Secretion , Intracellular Membranes/physiology , Ion Channels , Islets of Langerhans/metabolism , Membrane Potentials/drug effects , Mitochondria/physiology , Oleic Acid/pharmacology , Proteins/genetics , Time Factors , Uncoupling Protein 2
3.
Eur J Endocrinol ; 144(2): 145-54, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11182751

ABSTRACT

OBJECTIVE: We earlier reported marked qualitative differences between the effect of 3,5,3'-tri-iodothyroacetic acid (Triac) and tri-iodothyronine (T3) on cardiac hypertrophy at equivalent thyroid-stimulating hormone (TSH)-suppressive doses. We have now extended these studies to specific cardiac parameters. Due to its rapid metabolic clearance rate, Triac is not suitable for TSH suppression and therefore the slowly metabolized 3,5,3',5'-tetraiodothyroacetic acid (Tetrac), the precursor of Triac, was studied. METHODS: Hypothyroid rats were infused over 13 days with 1.5-40.5 nmol Tetrac/day per 100 g body weight (BW) or with 0.5-13.5 nmol thyroxine ((4)T4)/day per 100 g BW. RESULTS: The responses of serum TSH and of hepatic monodeiodinase type 1 were parallel for both hormones, their potency ratios could therefore be compared. Tetrac was revealed as being only half as active on hepatic monoiodinase type 1 despite a similar serum TSH levels. Tetrac can therefore be considered to have a preferential action on serum TSH suppression. The cardiac effects on Ca2+-ATPase (SERCA 2a) and monodeiodinase type 1 activity were qualitatively different and therefore one cannot give an overall quantitative estimate of these differences. The results showed clearly, however, that Tetrac is less efficient for all parameters studied, namely induction of cardiac hypertrophy, alpha-myosin heavy chain mRNA, monodeiodinase type 1 activity and mRNA levels of the sarcoplasmic SERCA 2a. CONCLUSION: We postulate therefore that, in the rat and possibly in man, Tetrac could represent a favorable alternative for suppression of serum TSH levels.


Subject(s)
Cardiomegaly/chemically induced , Thyrotropin/antagonists & inhibitors , Thyroxine/analogs & derivatives , Thyroxine/pharmacology , Animals , Calcium-Transporting ATPases/genetics , Cardiomegaly/pathology , Iodide Peroxidase/genetics , Iodide Peroxidase/metabolism , Isoenzymes/genetics , Isoenzymes/metabolism , Liver/enzymology , Male , Myocardium/enzymology , Myocardium/pathology , Organ Size/drug effects , Pituitary Gland/enzymology , RNA, Messenger/metabolism , Rats , Rats, Inbred Strains , Thyrotropin/blood
4.
Am J Physiol ; 277(3): E521-8, 1999 09.
Article in English | MEDLINE | ID: mdl-10484365

ABSTRACT

A comprehensive metabolic study was carried out to understand how chronic exposure of pancreatic beta-cells to fatty acids causes high basal secretion and impairs glucose-induced insulin release. INS-1 beta-cells were exposed to 0.4 mM oleate for 3 days and subsequently incubated at 5 or 25 mM glucose, after which various parameters were measured. Chronic oleate promoted triglyceride deposition, increased fatty acid oxidation and esterification, and reduced malonyl-CoA at low glucose in association with elevated basal O(2) consumption and redox state. Oleate caused a modest (25%) reduction in glucose oxidation but did not affect glucose usage, the glucose 6-phosphate and citrate contents, and the activity of pyruvate dehydrogenase of INS-1 cells. Thus changes in glucose metabolism and a Randle-glucose/fatty acid cycle do not explain the altered secretory properties of beta-cells exposed to fatty acids. The main response of INS-1 cells to chronic oleate, which is to increase the oxidation and esterification of fatty acids, may contribute to cause high basal insulin secretion via increased production of reducing equivalents and/or the generation of complex lipid messenger molecule(s).


Subject(s)
Glucose/metabolism , Insulin/metabolism , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Lipid Metabolism , Oleic Acid/pharmacology , Cell Line , Energy Metabolism/drug effects , Insulin Secretion , Oxidation-Reduction/drug effects , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...